Patients Receiving BVA Stayed 2.5 Fewer Days in Hospital Resulting in Reduced Costs of Care Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) — Daxor Corporation, the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic blood test in reducing hospital length of stay […]
Coronary/Structural Heart
Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting
Statistically Significant Reduction in CV Mortality and HF Rehospitalizations as Compared to IV Diuretics at 30 and 90 Days MINNEAPOLIS, Oct. 03, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the results of the AVOID-HF […]
Valbiotis Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hypercholesterolemia
TOTUM•070 demonstrates excellent results in volunteers with blood LDL cholesterol levels above 130 mg/dl at randomization, its commercially targeted population and the primary subpopulation of the HEART study: Increased and lasting efficacy on blood LDL cholesterol levels, with a reduction of 13.7% after three months and 14.3% after six months, […]
ZOLL Selected to Exhibit TherOx SSO2 Therapy at Vizient Innovative Technology Exchange
CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL, an Asahi Kasei company, has been selected to exhibit SuperSaturated Oxygen (SSO2) Therapy, which delivers high levels of dissolved oxygen directly to the heart following severe heart attack, at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s largest member-driven health care performance improvement company, will hold the […]
CYTOKINETICS PRESENTS NEW DATA FROM REDWOOD-HCM OLE IN LATE BREAKING CLINICAL TRIAL SESSION AT THE HFSA ANNUAL SCIENTIFIC MEETING
Treatment with Aficamten Associated with Significant Improvements in Symptoms and Quality of Life Additional Data Presented in Poster Session Shows Patients with Worsening Heart Failure and LVEF ≤30% Have Disproportionately High Risk of Heart Failure Hospitalization SOUTH SAN FRANCISCO, Calif., Oct. 02, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today […]
New Studies Validating the Uniqueness of the BVA-100® Blood Test for Heart Failure Patients Compared to Pressure Measures
Presented at Key Scientific Society Meeting – Commonly Used Pressure Measures for Volume Assessment Proven Not Equivalent to BVA Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data from Duke Heart validating the benefits of the […]
ImpediMed Announces Two Posters at Heart Failure Society of America Annual Scientific Meeting That Demonstrate Utility of SOZO® Digital Health Platform for Heart Failure Patients
CARLSBAD, Calif. and BRISBANE, Australia, Sept. 30, 2022 /PRNewswire/ — ImpediMed Limited (ASX: IPD), a global medical technology company using bioimpedance spectroscopy (BIS) to generate powerful data to maximize patient health, today announced two poster presentations at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, which is taking place Sept. 30 to Oct. […]
Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessions
New Analysis Demonstrates Successful Reduction or Withdrawal of Standard of Care Therapies in Patients Treated with Aficamten SOUTH SAN FRANCISCO, Calif., Sept. 30, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today presented new data on the reduction and withdrawal of background standard of care medical therapy in patients treated […]
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
— Pediatric efficacy data for both patients show initial improvements across clinical, functional and biomarker endpoints with six to nine months of follow-up; positive results including protein expression obtained at three and six months consistent with adult cohorts at similar timeframe— — Results demonstrate sustained clinical benefit across all parameters in adult […]
Ultromics joins FNIH Partnership to Transform Heart Failure Detection
The FNIH’s Accelerating Medicines Partnership® Heart Failure OXFORD, England, Sept. 29, 2022 /PRNewswire/ — Ultromics, a digital health technology company pioneering the development of transformative heart failure diagnostics, has joined as a full partner The Accelerating Medicines Partnership® Heart Failure (AMP® HF) including the National Institutes of Health (NIH) and the National Heart Lung and Blood Institute (NHLBI), managed […]
Recent
Popular
- No commented posts yet